Novaliq is a pharmaceutical company for the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first water-free technology for ophthalmology. Novaliq offers an industry-leading portfolio addressing today’s unmet medical needs of millions of eye patients:
NovaTears® improves the signs and symptoms of dry eye disease and is marketed under CE-approval in Australia/New Zealand by AFT Pharmaceuticals and in Europe as EvoTears® by Ursapharm.
Two drugs are in the late stage of clinical development:
CyclASol® is an anti-inflammatory and immunomodulating drug for the treatment of DED with a demonstrated early onset of action and excellent tolerability
NOV03 is the first drug addressing evaporative DED associated with meibomian gland dysfunction
For more information, please visit www.novaliq.com